Geode Capital Management LLC Boosts Stake in Singular Genomics Systems, Inc. (NASDAQ:OMIC)

Geode Capital Management LLC raised its holdings in shares of Singular Genomics Systems, Inc. (NASDAQ:OMIC) by 7.1% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 17,962 shares of the company’s stock after buying an additional 1,193 shares during the quarter. Geode Capital Management LLC owned about 0.72% of Singular Genomics Systems worth $282,000 as of its most recent filing with the Securities & Exchange Commission.

Singular Genomics Systems Price Performance

Singular Genomics Systems stock opened at $19.80 on Tuesday. Singular Genomics Systems, Inc. has a 52 week low of $5.34 and a 52 week high of $23.41. The business has a 50-day simple moving average of $20.76 and a 200 day simple moving average of $14.07. The company has a quick ratio of 6.67, a current ratio of 7.37 and a debt-to-equity ratio of 0.04. The stock has a market cap of $49.74 million, a price-to-earnings ratio of -0.56 and a beta of 1.82.

Singular Genomics Systems (NASDAQ:OMIC) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($6.72) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($8.05) by $1.33. Singular Genomics Systems had a negative return on equity of 57.87% and a negative net margin of 3,237.89%. The firm had revenue of $0.41 million during the quarter, compared to analysts’ expectations of $0.74 million.

Singular Genomics Systems Profile

Singular Genomics Systems, Inc, a life science technology company, develops next generation sequencing and multiomics technology for researchers and clinicians to advance science and medicine. The company is involved in the developing of G4, consisting of G4 instrument and associated consumables for various applications, such as max read kits for single cell sequencing, rare variant detection with high-definition sequencing, gene fusion detection with ring-seq, and extended range sequencing; and PX instrument and associated consumables for applications comprising single cell gene expression and proteomics, in situ RNA sequencing, and spatial RNA and proteomics applications for tissue.